<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694551</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15262</org_study_id>
    <secondary_id>106346</secondary_id>
    <secondary_id>20-14555-05-01</secondary_id>
    <nct_id>NCT00694551</nct_id>
  </id_info>
  <brief_title>PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment</brief_title>
  <official_title>Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot Immunotherapy Study of Combination Prostate Specific Membrane Antigen (PSMA) and T-cell
      receptor Î³ alternate reading frame protein (TARP) Peptide With Poly IC-LC Adjuvant in Human
      Leukocyte Antigens (HLA)-A2 (+) Patients With Elevated prostatic specific antigen (PSA) After
      Initial Definitive Treatment

      The purpose of the study is to see if the PSMA/TARP proteins in the vaccine, along with the
      Hiltonol, can arouse and train the immune system to kill the prostate cancer cells. Prostate
      cancer is the most common cancer and is the second leading cause of cancer deaths in U.S.
      males. It is curable when it is confined to the prostate (kept from spreading) using surgery
      or radiation treatments. In some patients the cancer can come back after these treatments.
      Treatment options for prostate cancer that comes back include procedures or medications which
      may have significant risks and side effects. Another plan is being looked at that uses the
      body's immune system to attack prostate cancer cells. A vaccine has been developed that has
      proteins found in prostate cancer cells. One of the proteins is called PSMA and the other is
      called TARP. In addition to these proteins, another substance called Poly IC-LC (Hiltonol)
      will be added to the vaccine to boost its ability to start the immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Objectives:

        1. Estimate the frequency of immunological efficacy of the vaccine by comparison of the in
           vitro enzyme-linked immunosorbent spot (ELISpot) test results, for each antigen (PSMA,
           TARP) from peripheral blood specimens collected during the periods of time defined as
           &quot;before&quot;, &quot;during&quot; and &quot;after&quot; vaccination.

        2. Study the safety and toxicity of varying doses of polypeptide vaccines:
           PSMA27-35-PSMA687-701 (VLAGGFFLLYRHVIYAPSSHNKYA) and TARP13-35 (LQLLKQSSRRLEHTFMFLRNFSL)
           administered with a fixed dose of Poly IC-LC (2 mg total/treatment) as adjuvant.

        3. Describe the impact of the vaccine on the pattern of PSA change in 2 subsets of
           patients: with castrate testosterone; with non-suppressed testosterone level/not on
           hormone therapy.

        4. Identify if there is a basis for selection of a dose of the PSMA and the TARP
           polypeptide vaccines for future phase II development of this vaccination strategy,
           considering the dose range tested.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2, 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Related Adverse Events - Grade 3 or Higher</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Number of participants with related Grade 3 or higher adverse events. Establish the safety and toxicity of varying doses of polypeptide vaccines PSMA and TARP administered with a fixed dose of Poly IC-LC as an adjuvant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Prostatic Specific Antigen (PSA) Doubling</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Number of Participants Who Had a Doubling of the PSA or Proceeded to Another Therapy.
Assess the impact of the vaccine on the pattern of PSA change in patients with castrate testosterone level and in patients with non-suppressed testosterone level not on hormone therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Did Not Have PSA Doubling</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Number of participants who did not have a PSA doubling before their last study visit, median 458 days from baseline PSA (55-613).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A. Level 100 mcg Peptide Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peptide vaccine dose level 100 mcg + Poly IC-LC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Level 300 mcg Peptide Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peptide vaccine dose level 300 mcg + Poly IC-LC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C. Level 1 mg Peptide Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peptide vaccine dose level 1 mg + Poly IC-LC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peptide Vaccine</intervention_name>
    <description>Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
    <arm_group_label>A. Level 100 mcg Peptide Vaccine</arm_group_label>
    <arm_group_label>B. Level 300 mcg Peptide Vaccine</arm_group_label>
    <arm_group_label>C. Level 1 mg Peptide Vaccine</arm_group_label>
    <other_name>Hiltonol</other_name>
    <other_name>poly IC-LC</other_name>
    <other_name>PSMA peptide vaccine</other_name>
    <other_name>TARP peptide vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly IC-LC</intervention_name>
    <description>Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).</description>
    <arm_group_label>A. Level 100 mcg Peptide Vaccine</arm_group_label>
    <arm_group_label>B. Level 300 mcg Peptide Vaccine</arm_group_label>
    <arm_group_label>C. Level 1 mg Peptide Vaccine</arm_group_label>
    <other_name>Hiltonol</other_name>
    <other_name>NSC-301463</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of histologically confirmed prostate cancer.

          -  Competence to understand the patient information and provide written informed consent,
             and willingness and ability to return to H. Lee Moffitt Cancer Center for planned
             treatments and follow-up.

          -  Absence of evidence of metastatic disease by current physical exam or by current
             imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI] pelvis,
             and bone scan within 60 days of first treatment).

          -  Patients not on hormone therapy (stratum &quot;N&quot;) must meet all of these:

               1. At least 1 year after prostatectomy, definitive prostate radiation, or other
                  definitive-intent local therapy.

               2. No testosterone suppression therapy for at least 6 months.

               3. PSA at least 1 ng/ml, on 2 measurements, at least 2 weeks apart.

               4. Testosterone level &gt;100 ng/ml, at start (&quot;noncastrate&quot;).

          -  Patients on hormone therapy (stratum &quot;Y&quot;) must meet all of these:

               1. On treatment with gonadotropin-releasing hormone (GnRH) agonist (or orchiectomy)
                  at least 6 months.

               2. testosterone level &lt;50 ng/ml, at start.

               3. PSA at least 1 ng/ml, on 2 measurements, at least 2 weeks apart.

          -  Laboratory values obtained 0-14 days prior to start of therapy:

               1. White blood count (WBC) over 3,500/micro L.

               2. Platelet count over 100,000 micro L.

               3. Hemoglobin over 10.0 g/dL.

               4. Serum creatinine up to 2.0 mg/dL.

               5. Alkaline phosphatase up to 2.5 x upper limit of normal (ULN).

               6. Aspartic transaminase (AST) up to 2.5 x ULN.

          -  Life expectancy at least 6 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

        Exclusion Criteria:

          -  Known standard therapy for the patient's disease that is potentially curative.

          -  A known immunodeficiency including HIV. Appropriate trials for individuals with HIV
             may be considered at a later date.

          -  History of other malignancy besides prostate cancer in the last 5 years, except
             non-melanoma skin cancer treated with local resection only. (The effect of study
             treatment on other, potentially dormant malignant diseases is not known).

          -  Use of oral or inhaled or parenteral corticosteroids or of other immunomodulatory
             drugs within the 60 days of start. [Use of steroids after start will be considered by
             the principal investigator (PI) on a case-by-case basis.]

          -  Use of estrogens (including herbal phytoestrogens) or ketoconazole within 30 days of
             start, or during the study.

          -  Failure to fully recover to grade 1 or better from effects of prior chemotherapy
             regardless of interval since last treatment.

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational agent
             in last 30 days (one month washout to start of treatment; patients could register but
             not start until the washout).

          -  Known hypersensitivity to one or more components of the study medication.

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayer Fishman, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <results_first_submitted>January 6, 2014</results_first_submitted>
  <results_first_submitted_qc>January 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2014</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>PSMA</keyword>
  <keyword>TARP</keyword>
  <keyword>immunology</keyword>
  <keyword>PSA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A. Level 100 mcg Peptide Vaccine</title>
          <description>Peptide vaccine dose level 100 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
        <group group_id="P2">
          <title>B. Level 300 mcg Peptide Vaccine</title>
          <description>Peptide vaccine dose level 300 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
        <group group_id="P3">
          <title>C. Level 1 mg Peptide Vaccine</title>
          <description>Peptide vaccine dose level 1 mg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who received any amount of study treatment were considered evaluable for toxicity.</population>
      <group_list>
        <group group_id="B1">
          <title>A. Peptide Vaccine</title>
          <description>Peptide vaccine dose Level 100 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
        <group group_id="B2">
          <title>B. Peptide Vaccine</title>
          <description>Peptide vaccine dose level 300 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
        <group group_id="B3">
          <title>C. Peptide Vaccine</title>
          <description>Peptide vaccine dose level 1 mg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="56" upper_limit="82"/>
                    <measurement group_id="B2" value="69.5" lower_limit="56" upper_limit="83"/>
                    <measurement group_id="B3" value="69" lower_limit="58" upper_limit="80"/>
                    <measurement group_id="B4" value="69.5" lower_limit="56" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Related Adverse Events - Grade 3 or Higher</title>
        <description>Number of participants with related Grade 3 or higher adverse events. Establish the safety and toxicity of varying doses of polypeptide vaccines PSMA and TARP administered with a fixed dose of Poly IC-LC as an adjuvant.</description>
        <time_frame>Up to 48 months</time_frame>
        <population>All participants who received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Level 100 mcg Peptide Vaccine</title>
            <description>Peptide vaccine dose Level 100 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
          <group group_id="O2">
            <title>B. Level 300 mcg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 300 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
          <group group_id="O3">
            <title>C. Level 1 mg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 1 mg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Related Adverse Events - Grade 3 or Higher</title>
          <description>Number of participants with related Grade 3 or higher adverse events. Establish the safety and toxicity of varying doses of polypeptide vaccines PSMA and TARP administered with a fixed dose of Poly IC-LC as an adjuvant.</description>
          <population>All participants who received treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Prostatic Specific Antigen (PSA) Doubling</title>
        <description>Number of Participants Who Had a Doubling of the PSA or Proceeded to Another Therapy.
Assess the impact of the vaccine on the pattern of PSA change in patients with castrate testosterone level and in patients with non-suppressed testosterone level not on hormone therapy.</description>
        <time_frame>Up to 48 months</time_frame>
        <population>29 patients who had serial PSA data, normalized by date and PSA.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Level 100 mcg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 100 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
          <group group_id="O2">
            <title>B. Level 300 mcg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 300 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
          <group group_id="O3">
            <title>C. Level 1 mg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 1 mg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Prostatic Specific Antigen (PSA) Doubling</title>
          <description>Number of Participants Who Had a Doubling of the PSA or Proceeded to Another Therapy.
Assess the impact of the vaccine on the pattern of PSA change in patients with castrate testosterone level and in patients with non-suppressed testosterone level not on hormone therapy.</description>
          <population>29 patients who had serial PSA data, normalized by date and PSA.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Did Not Have PSA Doubling</title>
        <description>Number of participants who did not have a PSA doubling before their last study visit, median 458 days from baseline PSA (55-613).</description>
        <time_frame>Up to 48 months</time_frame>
        <population>29 patients who had serial PSA data, normalized by date and PSA.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Level 100 mcg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 100 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
          <group group_id="O2">
            <title>B. Level 300 mcg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 300 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
          <group group_id="O3">
            <title>C. Level 1 mg Peptide Vaccine</title>
            <description>Peptide vaccine dose level 1 mg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Did Not Have PSA Doubling</title>
          <description>Number of participants who did not have a PSA doubling before their last study visit, median 458 days from baseline PSA (55-613).</description>
          <population>29 patients who had serial PSA data, normalized by date and PSA.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A. Peptide Vaccine</title>
          <description>Peptide vaccine dose Level 100 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
        <group group_id="E2">
          <title>B. Peptide Vaccine</title>
          <description>Peptide vaccine dose level 300 mcg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
        <group group_id="E3">
          <title>C. Peptide Vaccine</title>
          <description>Peptide vaccine dose level 1 mg
Peptide Vaccine: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough - Grade 2 -</sub_title>
                <description>PSMA: Unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="29" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Feverr (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="22" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="29" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="22" subjects_affected="7" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="19" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="14" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="34" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" events="46" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" events="38" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mayer Fishman, M.D., Ph.D.</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-4398</phone>
      <email>mayer.fishman@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

